
HarborSite
Research-stage platform for inserting therapeutic genes into safe genomic sites with engineered recombinases
- Industry
- Biotech
- Based in
- United States
Verified revenue: not connected yet
Is HarborSite yours? Claim this page and connect Stripe, the App Store or Google Play: your MRR and growth show here, read straight from the source.
About
HarborSite is a Harvard/Wyss Institute spinoff developing engineered recombinase enzymes to insert full-length therapeutic genes into safe sites in the genome, aiming at one-time treatments for genetic and age-related diseases. It is at research stage, with an initial focus on liver and blood cells. It is based in Boston, US, and is backed by Armenia-based SmartGate VC.
Team
- Erik Aznauryan, Co-founder and CEO (Founder)
- George Church, Co-founder and Scientific Advisory Board Chair (Founder)
- Tina Lebar, Co-founder and Scientific Advisory Board Member (Founder)
Audience
Followers on social networks
Profile data from Stanbase.